Does Mirikizumab treat colitis?

Mirikizumab (Mirikizumab)-Omvoh is a highly specific humanized IgG4 monoclonal antibody directed against interleukin-23 (IL-23). It is mainly used to treat ulcerative colitis (UC), a chronic autoimmune disease characterized by intestinal inflammation, which has a significant impact on patients' quality of life. Militizumab was developed to provide a new treatment option for patients with moderate to severe ulcerative colitis who have responded poorly to or are intolerant to conventional treatments.

Milizumab was approved in Japan in March 2023, becoming the first IL-23 monoclonal antibody approved for this indication. Its approval marks an important advance in the treatment of ulcerative colitis. Milizumab is approved not only for induction therapy but also for maintenance therapy. This means that it can help patients continue to maintain remission and avoid recurrence after controlling the disease in the early stages.

The mechanism of action of Militizumab is mainly by blocking theIL-23 signaling pathway to reduce immune responses related to inflammation. IL-23 plays a key role in the immune system, exacerbating intestinal inflammation by promoting the proliferation and differentiation of inflammatory cells. By inhibiting this pathway, militizumab can effectively reduce intestinal inflammation and improve patients' clinical symptoms, such as abdominal pain, diarrhea, and bleeding.

In clinical trials, militizumab showed good efficacy and safety. In studies of patients with moderately to severely active ulcerative colitis, many participants experienced significant improvement in symptoms after treatment with militizumab, and some patients even achieved clinical remission. In addition, the side effects of militizumab are generally relatively controllable, mainly including the risk of infection and injection site reactions. These risks are relatively manageable under the supervision of doctors.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/37389706/